Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
暂无分享,去创建一个
Y. Ando | H. Tanii | S. Oizumi | H. Minami | K. Kitagawa | N. Kiyota | Y. Komatsu | Y. Fujiwara | S. Yuki | M. Sawaki | A. Mitsuma | Sachi Morita | M. Inada | J. Kimura
[1] Richard Van Noorden. nature news 実験室は、安全な職場ではない , 2013 .
[2] H. Tanii,et al. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors , 2012, Investigational New Drugs.
[3] K. J. Henley,et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. , 2011, Blood.
[4] S. Lonial,et al. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes , 2011, Leukemia.
[5] S. Ramalingam,et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Lane,et al. Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Atadja. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.
[8] R. Johnstone,et al. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.
[9] H. Kovar,et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.
[10] E. Olson,et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.
[11] Stephen L. Lessnick,et al. EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma , 2008, PloS one.
[12] A. Unami,et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. , 2007, European journal of pharmacology.
[13] A. Patnaik,et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule , 2007 .
[14] P. Gibbs,et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Bhalla,et al. A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.
[16] Y. Iwamoto,et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.
[17] Y. Iwamoto,et al. Identification of p21 WAF1/CIP1 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003, The Journal of Biological Chemistry.
[18] Y. Iwamoto,et al. Identification of p21 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003 .